Erlotinib in a previously treated advanced non-small cell lung cancer elderly patient: a clinical case.

Erlotinib is a small molecule that selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase activity. It demonstrated single-agent activity in patients with non-small cell lung cancer (NSCLC). Single-agent chemotherapy is the standard treatment of advanced NSCLC elderly patients. We report a case of a partial response in a 76-year-old never-smoker female affected by advanced lung adenocarcinoma refractory to first- and second-line chemotherapy. [ABSTRACT FROM AUTHOR]